SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus Abstract #2812

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Aim(s): The present retrospective multicenter project is analyzing the predictive/prognosis role of MGMT, NDRG-1 and PHLDA-3 in patients treated with advanced PanNET treated CAPTEM or everolimus.
Materials and methods: IHC nuclear staining for MGMT and PHLDA-3 is being scored as 0, 1-5%, 6-50% and ≥ 51%. For NDRG-1, we are using a cytoplasmic score from 0 to 2 based on distribution pattern (null, patched or diffuse).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Antonio Viudez

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1420 A New Immunohistochemistry Prognostic Score (IPS) Based on MGMT, NDRG-1 and PHLDA-3 for Recurrence and Survival in Resected Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: In PanNET tumors contradictory data about the prognostic role of MGMT (O6-methylguanine DNA methyltransferase) has been published. NDRG-1 (N-myc downstream-regulated gen-1) and PHLDA-3 (Pleckstrin homology-like domain family A member 3) immunohistochemistry (IHC) expressions have been evaluated in several solid malignant tumors, but their roles in PanNET remain unknown
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Antonio Viudez
#2745 Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
Introduction: Lung carcinoids (LCs) are rare and slow growing primary lung neuroendocrine tumors. The WHO classify LCs into atypical and typical carcinoids. Recent studies have shown that the reproducibility of LCs classification and its prognostic efficacy have high interobserver variability
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Saurabh V Laddha
#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, ...
#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy
Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Dr. Mauro Cives
#1316 Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort.
Introduction: LOXL2 is a key protein to epithelial to mesenchymal transition. We showed LOXL2 has a role as a prognostic marker in 115 GEP-NET cases (training cohort (TC)).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr. Jorge Barriuso
Keywords: LOXL2